Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California. Show more

Location: 1850 Gateway Drive, San Mateo, CA, 94404, United States | Website: https://talphera.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare

Market Cap

61.52M

52 Wk Range

$0.38 - $1.57

Previous Close

$1.32

Open

$1.32

Volume

77,392

Day Range

$1.32 - $1.39

Enterprise Value

40.24M

Cash

21.29M

Avg Qtr Burn

-2.796M

Insider Ownership

28.41%

Institutional Own.

38.16%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DSUVIA (sufentanil) Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nafamostat (Niyad™) Details Medical device	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zalviso US (sufentanil) Details Post operative acute pain	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.